
In a double-blind crossover trial, ambulatory oxygen significantly improved 6-minute walk distance, reduced dyspnoea and fatigue, and prevented desaturation in patients with fibrotic interstitial lung disease (F-ILD). Patients preferred oxygen over placebo, confirming clinical benefit beyond placebo effect and supporting shared decision-making in oxygen therapy.
Like
Save
Share